houttuynia
cordata
thunb
tradit
herb
use
clear
heat
elimin
toxin
also
use
treatment
sever
acut
respiratori
syndrom
sar
vitro
crude
h
cordata
polysaccharid
chcp
exhibit
potent
anticomplementari
activ
classic
altern
pathway
act
compon
complement
system
without
interf
coagul
system
studi
investig
prevent
effect
chcp
acut
lung
injuri
ali
induc
hemorrhag
shock
plu
lipopolysaccharid
lp
instil
twohit
lpsinduc
fever
rat
chcp
significantli
attenu
pulmonari
injuri
twohit
ali
model
reduc
pulmonari
edema
protein
exud
bronchoalveolar
lavag
fluid
balf
addit
reduc
deposit
complement
activ
product
lung
improv
oxidantantioxid
imbal
moreov
chcp
administr
inhibit
fever
rat
reduc
number
leukocyt
restor
serum
complement
level
inhibit
inappropri
activ
complement
system
chcp
may
play
import
role
benefici
effect
inflammatori
diseas
anticomplementari
polysaccharid
like
among
key
substanc
heatclear
function
h
cordata
complement
system
compos
plasma
membranebound
protein
consid
nonspecif
host
immun
respons
activ
immedi
injuri
greater
degre
resuscit
howev
inappropri
activ
complement
system
demonstr
play
role
pathogenesi
wide
rang
autoimmun
disord
acut
inflammatori
diseas
tissu
injuri
anaphylatoxin
cleav
respect
complement
compon
complement
activ
may
trigger
degranul
endotheli
cell
mast
cell
phagocyt
induc
inflammatori
respons
well
fatal
shocklik
syndrom
modul
complement
activ
could
benefici
treat
variou
complementassoci
diseas
acut
lung
injuri
ali
character
respiratori
dysfunct
hypoxemia
presenc
diffus
pulmonari
infiltr
widespread
lung
inflamm
increas
pulmonari
vascular
permeabl
accumul
activ
neutrophil
lung
acut
respiratori
distress
syndrom
ard
sever
form
ali
complement
activ
earli
step
ali
classic
pathway
altern
pathway
loss
endotheli
integr
process
aliard
also
caus
injur
pulmonari
cell
releas
tissu
factor
enzym
would
lead
initi
complement
cascad
cycl
complement
activ
lung
injuri
consequ
form
henc
applic
complement
inhibitor
novel
treatment
strategi
infecti
fever
ali
fever
anoth
characterist
symptom
infecti
diseas
one
complex
nonspecif
host
defens
respons
infect
report
hyperactiv
complement
system
also
involv
fever
tradit
chines
medicin
action
clear
heat
elimin
toxin
whole
plant
houttuynia
cordata
thunb
saururacea
commonli
use
treatment
pulmonari
symptom
includ
lung
abscess
dyspnea
phlegm
cough
well
infecti
diseas
anaphylaxi
cancer
viral
infect
chines
multiherb
remedi
h
cordata
princip
ingredi
use
treatment
prevent
sever
acut
respiratori
syndrom
sar
found
signific
anticomplementari
activ
previou
studi
indic
crude
h
cordata
polysaccharid
chcp
flavonoid
major
anticomplementari
principl
plant
anticomplementari
polysaccharid
show
potent
effect
complementassoci
diseas
vivo
presenc
lipopolysaccharid
lp
prototyp
endotoxin
blood
caus
immedi
activ
complement
cascad
report
chcp
could
amelior
lpsinduc
ali
mice
reduc
complement
activ
product
deposit
lung
tissu
howev
still
unclear
whether
effect
direct
result
chcp
anticomplementari
activ
vivo
herein
benefici
effect
chcp
ali
evalu
use
twohit
ali
rat
model
induc
hemorrhag
shock
plu
lp
instil
suscept
lung
injuri
specif
vivo
anticomplementari
activ
chcp
also
assess
besid
pulmonari
infect
fever
anoth
typic
indic
heatclear
tradit
chines
medicin
tcm
therefor
paper
investig
vivo
antipyret
effect
anticomplementari
activ
chcp
febril
rat
model
induc
lp
dri
whole
plant
h
cordata
purchas
shanghai
huayu
chines
materia
medica
co
ltd
shanghai
china
identifi
one
author
dr
yan
lu
voucher
specimen
deposit
depart
pharmacognosi
school
pharmaci
fudan
univers
shanghai
china
chcp
prepar
process
water
extract
alcohol
precipit
deprotein
previous
report
dri
whole
plant
h
cordata
ground
defat
ethanol
residu
extract
hot
water
water
extract
concentr
precipit
trichloroacet
acid
remov
protein
supernat
dialyz
run
water
day
precipit
ad
volum
ethanol
precipit
lyophil
yield
polysaccharid
chcp
total
carbohydr
content
determin
phenolsulfur
acid
use
dgalactos
standard
mhydroxybiphenyl
method
use
test
uron
acid
content
dgalacturon
acid
standard
concentr
total
protein
evalu
use
coomassi
brilliant
blue
method
bovin
serum
albumin
standard
high
perform
gel
permeat
chromatographi
hpgpc
carri
analys
molecular
weight
chcp
tskgel
gmpwxl
column
mm
mm
tosoh
japan
ga
chromatographi
gc
use
analyz
monosaccharid
composit
complet
hydrolyz
chcp
hewlettpackard
wilmington
usa
fit
capillari
column
buffer
barbitol
buffer
solut
bb
contain
mmoll
mg
mmoll
ca
gvbmgegta
veron
buffer
salin
contain
mmoll
mg
mmoll
ca
anticomplementari
activ
classic
pathway
studi
base
mayer
modifi
method
bb
buffer
complement
sourc
dilut
serum
guinea
pig
chosen
give
submaxim
lysi
absenc
complement
inhibitor
chcp
heparin
use
posit
control
dissolv
bb
differ
dilut
sampl
incub
guinea
pig
serum
sheep
erythrocyt
cellsml
rabbit
antisheep
erythrocyt
antibodi
min
reaction
mixtur
centrifug
g
min
optic
densiti
od
supernat
measur
nm
sampl
control
dilut
blank
control
lysi
control
prepar
condit
correct
absorb
dilut
chcp
sampl
obtain
subtract
absorb
sampl
control
valu
activ
determin
mean
triplic
measur
express
inhibit
ch
accord
method
klerx
et
al
sampl
dissolv
gvbmgegta
anticomplementari
assay
altern
pathway
sampl
mix
dilut
nh
rabbit
erythrocyt
ad
follow
incub
min
cell
lysi
measur
describ
inhibit
present
ap
identif
target
chcp
conduct
use
complementdeplet
cdeplet
sera
describ
literatur
six
compon
complement
system
select
possibl
target
differ
dilut
antiserum
incub
volum
nh
min
centrifug
supernat
incub
erythrocyt
ea
bb
cell
lysi
measur
antiserum
dilut
nh
hemolyt
capac
thu
determin
optim
dilut
antisera
antisera
dilut
incub
volum
nh
min
centrifug
supernat
store
aliquot
cdeplet
sera
target
identif
perform
evalu
capac
variou
cdeplet
sera
restor
hemolyt
capac
chcptreat
serum
optim
concentr
chcp
mgml
suffici
complet
inhibit
hemolyt
activ
dilut
nh
cp
sensit
erythrocyt
individu
cdeplet
serum
ad
sampletr
nh
mixtur
incub
min
centrifug
percentag
hemolysi
calcul
capac
cdeplet
sera
lyse
erythrocyt
also
assess
incub
cdeplet
serum
directli
erythrocyt
condit
control
vehicl
lysi
complement
sampl
control
treat
way
influenc
chcp
coagul
system
examin
determin
recalcif
time
rt
thrombin
time
tt
platelet
poor
plasma
ppp
prepar
anticoagul
blood
guinea
pig
guinea
pig
anesthet
gkg
urethan
intraperiton
ip
right
common
carotid
arteri
separ
cannul
angiocath
shanghai
puyi
medic
instrument
co
ltd
shanghai
china
fill
ww
trisodium
citrat
blood
sampl
whole
blood
guinea
pig
mix
trisodium
citrat
vv
centrifug
min
g
supernat
obtain
use
ppp
sampl
incub
ppp
min
total
cacl
moll
thrombin
ad
assay
rt
tt
respect
heparin
mgl
use
posit
control
experi
male
sd
rat
fast
overnight
h
free
access
water
twohit
ali
anim
model
induc
hemorrhag
shockresuscit
lp
instil
use
studi
rat
randomli
divid
six
group
sham
ali
model
prednison
mgkg
group
well
chcp
group
mgkg
anim
anesthet
gkg
urethan
ip
right
common
carotid
arteri
cannul
angiocath
indwel
needl
fill
heparin
monitor
mean
arteri
pressur
map
blood
sampl
resuscit
heparin
perform
inject
ml
heparin
angiocath
prevent
clot
hemorrhag
shock
initi
blood
withdraw
lead
reduct
map
mmhg
min
blood
pressur
maintain
blood
withdraw
map
higher
mmhg
infus
ml
normal
salin
ns
map
less
mmhg
hypotens
period
min
rat
resuscit
transfus
withdrawn
blood
h
either
lp
mgkg
ns
ns
alon
administ
intratrach
chcp
mgkg
mgkg
mgkg
dissolv
salin
given
intragastr
ig
min
lp
instil
rat
posit
control
group
receiv
singl
dose
prednison
mgkg
ip
sham
anim
underw
surgic
procedur
without
hypotens
process
receiv
intratrach
instil
ns
serum
sampl
anim
obtain
right
carotid
arteri
h
administr
lp
anim
breath
spontan
experi
sacrif
h
lp
administr
lower
lobe
right
lung
use
determin
wetdri
weight
wd
ratio
harvest
weigh
immedi
dri
h
reweigh
upper
lobe
right
lung
fix
immedi
formaldehyd
routin
paraffin
embed
sampl
cut
section
stain
haematoxylin
eosin
h
e
detect
lung
histopatholog
alter
sever
lung
injuri
blindli
quantifi
pathologist
base
microscop
chang
includ
extent
diseas
alveolar
wall
thick
exud
pulmonari
congest
inflamm
degre
injuri
grade
normal
sever
categori
deposit
complement
activ
product
determin
use
immunohistochem
stain
rabbit
antihuman
bronchoalveolar
lavag
fluid
balf
collect
immedi
sacrific
lobe
left
lung
lavag
total
volum
ml
salin
balf
centrifug
g
min
cellfre
supernat
collect
store
assay
total
cell
count
perform
neubauer
count
chamber
leukocyt
classif
examin
count
least
cellssmear
prepar
use
cytospin
wrightgiemsa
stain
obtain
valu
repres
percentag
neutrophil
lymphocyt
total
leukocyt
concentr
total
protein
determin
coomassi
brilliant
blue
method
assay
superoxid
dismutas
sod
activ
malondialdehyd
mda
content
carri
use
commerci
kit
sera
collect
differ
time
test
hemolyt
activ
accord
mayer
method
serum
complement
activ
h
quantifi
rel
chang
normal
initi
valu
h
content
complement
compon
sera
collect
h
measur
immunonephelometr
method
instruct
commerci
kit
fever
experi
model
group
adult
male
wistar
rat
g
hous
least
day
experi
room
temperatur
rel
humid
lightdark
cycl
rectal
temperatur
determin
twice
everi
day
day
experi
two
rat
hous
one
cage
fast
h
free
access
water
rat
stabl
baselin
temperatur
select
experi
determin
rectal
temperatur
three
time
everi
min
divid
six
group
n
sham
group
lpsinduc
model
group
chcp
differ
dose
mgkg
group
aspirin
mgkg
group
drug
dilut
normal
salin
oral
administr
drug
administr
min
lp
inject
intraperiton
ip
induc
fever
volum
salin
mlkg
without
lp
inject
sham
group
bodi
temperatur
record
everi
min
h
lp
inject
chang
bodi
temperatur
calcul
thermal
respons
index
tri
h
group
evalu
area
temperaturetim
curv
calcul
sum
area
trapezoid
everi
two
data
point
area
trapezoid
curv
calcul
rat
anesthet
gkg
urethan
ip
serum
blood
sampl
collect
complement
activ
assay
leukocyt
count
respect
total
number
leukocyt
peripher
blood
detect
neubauer
count
chamber
quantit
data
express
statist
analysi
carri
use
spss
ibm
chicago
usa
differ
among
group
assess
oneway
analysi
varianc
anova
follow
dunnett
test
nonparametr
data
evalu
use
mannwhitney
test
p
valu
less
consid
statist
signific
chcp
dark
brown
powder
solubl
water
total
carbohydr
uron
acid
protein
content
chcp
respect
hpgpc
analysi
show
chcp
contain
one
major
polysaccharid
sever
minor
one
molecular
weight
rang
kda
support
inform
fig
gc
analysi
indic
complex
macromolecul
link
multipl
monosacchrid
mainli
includ
glucos
galactos
arabinos
rhamnos
ratio
togeth
chcp
show
stronger
inhibitori
effect
heparin
classic
pathway
inhibit
altern
pathway
littl
weaker
compar
heparin
fig
ch
ap
valu
mgml
mgml
n
respect
target
chcp
complement
activ
cascad
indic
fig
nh
led
hemolysi
complementcontrol
group
chcp
concentr
mgml
exhibit
strong
inhibitori
effect
hemolysi
hemolyt
percentag
induc
cdeplet
sera
less
indic
cdeplet
sera
would
lyse
erythrocyt
independ
treat
chcp
serum
deplet
still
restor
hemolyt
activ
suggest
chcp
block
complement
cascad
sera
also
restor
hemolysi
markedli
howev
chcp
nearli
abolish
hemolysi
serum
ad
hemolysi
partli
restor
result
suggest
chcp
mainli
block
may
interact
shown
tabl
histopatholog
find
lung
tissu
h
e
stain
show
clear
pulmonari
structur
littl
cellular
influx
sham
group
wherea
ali
anim
exhibit
sever
lung
injuri
includ
mark
interstiti
edema
septal
thicken
hemorrhag
inflammatori
cell
infiltr
fig
prednison
effect
suppress
lung
damag
administr
chcp
mgkg
mgkg
significantli
attenu
neutrophil
accumul
alveolar
wall
thicken
intraalveolar
exud
howev
seriou
pulmonari
inflamm
still
seen
lowdos
group
chcp
mgkg
result
confirm
total
lung
injuri
score
list
tabl
result
immunohistochemistri
show
low
level
yellowstain
deposit
lung
sham
group
intens
deposit
model
group
treatment
chcp
mgkg
significantli
reduc
complement
activ
product
deposit
lung
ali
rat
fig
shown
tabl
lung
wd
ratio
ali
model
group
notabl
higher
sham
group
lung
wd
ratio
significantli
reduc
mgkg
chcp
group
respect
well
prednison
group
compar
ali
rat
elev
protein
concentr
balf
import
marker
injuri
pulmonari
alveolarcapillari
barrier
pulmonari
protein
exud
significantli
reduc
chcp
dose
mgkg
prednison
fig
indic
treatment
amelior
alveolarcapillari
barrier
damag
ali
cell
balf
classifi
count
estim
inflammatori
respons
ali
balf
sham
anim
contain
minim
number
leukocyt
lowest
percentag
neutrophil
highest
proport
lymphocyt
develop
ali
elicit
massiv
recruit
total
leukocyt
neutrophil
lung
shown
fig
number
leukocyt
percentag
neutrophil
balf
appar
higher
ali
anim
sham
anim
proport
lymphocyt
balf
much
lower
administr
chcp
mgkg
prednison
appar
suppress
accumul
leukocyt
attenu
lung
neutrophilia
indic
reduct
total
leukocyt
count
neutrophil
percentag
balf
good
abil
inhibit
decreas
lymphocyt
shown
fig
pathogenesi
ali
result
signific
decreas
sod
activ
mark
increas
mda
content
comparison
sham
group
treatment
prednison
chcp
dose
mgkg
significantli
figur
hemolyt
assay
individu
compon
util
cdeplet
serum
chcptreat
serum
mix
variou
deplet
sera
capac
deplet
sera
restor
classic
pathway
hemolysi
estim
ad
sheep
antibodysensit
erythrocyt
result
express
hemolyt
percentag
data
list
n
indic
chcp
reduc
consumpt
complement
compon
fig
bodi
temperatur
tri
experi
bodi
temperatur
rat
sham
group
maintain
normal
rang
minor
chang
bodi
temperatur
tri
model
group
significantli
higher
sham
group
min
h
except
normal
period
min
fig
shown
fig
chcp
mgkg
treatment
significantli
inhibit
fever
induc
lp
min
h
aspirin
also
inhibit
temperatur
increas
similar
result
found
tri
fig
shown
fig
complement
level
model
group
significantli
decreas
compar
sham
group
lp
inject
increas
number
leukocyt
peripher
blood
model
rat
fig
chcp
mgkg
treatment
partli
restor
complement
level
serum
signific
effect
observ
lowdos
group
chcp
mgkg
aspirin
group
chcp
group
mgkg
mgkg
aspirin
group
significantli
inhibit
increas
leukocyt
peripher
blood
induc
lp
heatclear
chines
medicin
well
known
effect
fever
inflamm
infecti
diseas
previou
studi
led
isol
seri
complement
inhibitor
medicin
indic
inhibit
excess
activ
complement
system
would
key
mechan
tcm
clear
heat
studi
anticomplementari
properti
chcp
elucid
vitro
vivo
vitro
experi
clearli
reveal
chcp
potent
anticomplementari
agent
affect
classic
pathway
altern
pathway
select
block
key
compon
complement
activ
cascad
demonstr
literatur
function
activ
classic
altern
pathway
make
total
protein
complement
system
second
abund
complement
protein
serum
glycoprotein
function
limit
activ
step
activ
classic
pathway
suggest
chcp
could
effect
treat
complementassoci
diseas
ali
lifethreaten
complic
variou
system
inflamm
pulmonari
disord
caus
mortal
rate
current
main
treatment
ali
applic
glucocorticoid
often
lead
sever
advers
reaction
long
treatment
henc
choic
agent
less
advers
effect
crucial
recoveri
ali
base
import
role
complement
activ
induct
inflammatori
respons
ali
ard
vivo
anticomplementari
activ
chcp
prevent
effect
ali
examin
twohit
ali
rat
model
ischemiareperfus
ir
injuri
follow
lp
instil
twohit
ali
rat
model
shown
induc
exagger
respons
suscept
lung
injuri
ir
believ
augment
neutrophilmedi
lung
injuri
prime
circul
neutrophil
increas
superoxid
product
activ
complement
system
known
necessari
full
develop
inflammatori
respons
tissu
injuri
associ
ir
pulmonari
injuri
base
ir
intratrach
instil
lp
induc
ideal
experiment
model
ali
result
pulmonari
injuri
great
balf
neutrophil
infiltr
histolog
examin
reveal
mark
inflamm
extens
alveolar
wall
thick
congest
well
diffus
interstiti
infiltr
ali
immunohistochemistri
show
overactiv
complement
ali
abundantli
increas
complement
activ
product
deposit
administr
chcp
especi
mgkg
significantli
improv
histolog
chang
combin
inhibit
overactiv
complement
system
regul
oxidantantioxid
imbal
well
reduc
number
leukocyt
neutrophil
balf
protect
effect
chcp
ali
also
accompani
decreas
pulmonari
edema
indic
lung
wd
weight
ratio
reduct
protein
concentr
balf
repres
preserv
pulmonari
epithelialendotheli
barrier
function
activ
complement
system
decreas
complement
level
serum
account
reduct
concentr
sham
group
minor
surgic
injuri
caus
slight
activ
complement
cascad
repres
minim
decreas
hemolysi
serum
twohit
ali
caus
significantli
complement
consumpt
oral
administr
chcp
mgkg
appar
reduc
consumpt
complement
system
effect
chcp
consist
result
vitro
complementtarget
test
system
activ
complement
system
gener
chemotact
activ
caus
blood
neutrophil
sequest
pulmonari
capillari
dramat
result
releas
toxic
oxygen
speci
destroy
pulmonari
endotheli
cell
well
basement
membran
oxidantantioxid
imbal
thought
underli
one
import
pathogenesi
lung
injuri
find
provid
strong
evid
ali
follow
overactiv
complement
system
close
link
product
oxygen
metabolit
lungsequest
neutrophil
experi
proport
neutrophil
actual
suppress
administr
chcp
suggest
chcp
potent
attenu
neutrophil
respiratori
burst
sod
import
antioxid
enzym
scaveng
superoxid
free
radic
mda
recogn
standard
measur
degre
oxid
pathogenesi
ali
result
decreas
sod
level
elev
mda
content
take
chcp
could
reduc
pulmonari
oxid
stress
modul
oxidantantioxid
balanc
lpsinduc
fever
classic
inflammatori
heat
model
character
high
bodi
temperatur
increas
leukocyt
hyperactiv
complement
system
studi
chcp
complement
inhibitor
aspirin
cyclooxygenas
inhibitor
significantli
decreas
bodi
temperatur
leukocyt
peripher
blood
lpsinduc
fever
rat
remark
chcp
mgkg
aspirin
could
inhibit
decreas
complement
level
fever
rat
indic
characterist
effect
chcp
complement
system
vivo
recent
bioactivityguid
fraction
chcp
led
isol
three
anticomplementari
homogen
polysaccharid
ch
ap
valu
mgml
similar
monosaccharid
composit
chcp
data
publish
result
confirm
anticomplementari
polysaccharid
key
materi
basi
benefici
effect
chcp
ali
fever
compos
larg
amount
monosaccharid
glucosid
bond
polysaccharid
complex
accur
control
qualiti
one
specif
analyt
method
multipl
method
use
comprehens
character
structur
chcp
includ
content
carbohydr
uron
acid
molecular
weight
monosaccharid
composit
conclus
studi
demonstr
chcp
amelior
twohit
ali
also
lpsinduc
fever
rat
associ
inhibit
excess
activ
complement
system
anticomplementari
polysaccharid
shown
play
import
role
heatclear
effect
h
cordata
moreov
chcp
interfer
coagul
system
chcp
could
promis
natur
complement
inhibitor
appli
treatment
complementassoci
diseas
